Related Experiment Video
Updated: May 31, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
[Functional impairment and radiologic fasciitis under erlotinib therapy]
S Osdoit1, E Wierzbicka, G Guillet
1Service de dermatologie-allergologie, CHU La Milétrie, CHU de Poitiers, 86000 Poitiers, France. sophie.osdoit@orange.fr
Background:
Targeted molecules are recent and valuable weapons in the management of certain cancers. Among them, erlotinib is an inhibitor of epidermal growth factor receptor approved in non-small lung cancer and pancreatic cancer after failure of first line treatment. Erlotinib is responsible for many cutaneous side effects. We report a case of acute symptomatic fasciitis that has occurred during erlotinib therapy. To our knowledge it is the first case described.
Case Report:
A 56-year-old man was treated with erlotinib for a metastatic non-small lung adenocarcinoma. Shortly after the treatment by erlotinib was introduced, he had a severe acneiform rash resistant to doxycycline treatment. After a year of treatment, he presented intense pain in the legs with functional impairment. Medical imaging confirmed fasciitis. It regressed along with the rash after using strong topical corticosteroids during ten days.
Discussion:
Besides bacterial fasciitis, inflammatory and oedematous fasciitis have varied aetiologies. The occurrence of a documented fasciitis during anti EGFR-therapy is original and raises the question of underlying mechanism. We suggest three pathophysiological mechanisms: spreading by contiguity; paraneoplastic fasciitis, or specific lesion of the fascia due to anti-EGFR.
Insights
Erlotinib, an EGFR inhibitor, can cause rare side effects like acute fasciitis. This case highlights a potential link between erlotinib therapy and inflammatory fasciitis, suggesting new mechanisms for EGFR inhibitor-related adverse events.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Targeted therapies, including epidermal growth factor receptor (EGFR) inhibitors like erlotinib, are crucial in cancer management.
- Erlotinib is approved for non-small cell lung cancer and pancreatic cancer post-first-line treatment.
- Cutaneous side effects are common with erlotinib, but other inflammatory conditions are less understood.
Observation:
- A 56-year-old man with metastatic non-small lung adenocarcinoma developed a severe acneiform rash during erlotinib treatment.
- Despite initial treatment, the patient later presented with intense leg pain and functional impairment.
- Medical imaging confirmed fasciitis, which resolved alongside the rash after topical corticosteroid therapy.
Findings:
- This case presents the first documented instance of acute symptomatic fasciitis occurring during erlotinib therapy.
- The fasciitis resolved with treatment, suggesting a potential link to the EGFR inhibitor.
- The patient's acneiform rash also improved with treatment, indicating a possible shared mechanism.
Implications:
- The occurrence of fasciitis during anti-EGFR therapy raises questions about underlying pathophysiological mechanisms.
- Potential mechanisms include direct fascial injury from anti-EGFR agents, paraneoplastic fasciitis, or contiguous spread from other inflammatory processes.
- This finding underscores the need for vigilance regarding rare inflammatory side effects of targeted cancer therapies.
